• News
  • Lifestyle
    • Recipes
    • Video
    • Lotto Results
    • Technology
  • Entertainment
  • Travel
  • Sport
  • Expat Life
  • Move to Australia
Sunday, January 24, 2021
Australian Times News
  • News
  • Lifestyle
    • Recipes
    • Video
    • Lotto Results
    • Technology
  • Entertainment
  • Travel
  • Sport
  • Expat Life
  • Move to Australia
No Result
View All Result
  • News
  • Lifestyle
    • Recipes
    • Video
    • Lotto Results
    • Technology
  • Entertainment
  • Travel
  • Sport
  • Expat Life
  • Move to Australia
No Result
View All Result
Australian Times News
No Result
View All Result
Home News

Multiple sclerosis drug may help treat COVID-19 and lead to faster recovery

Synairgen found that when SNG001 was given to patients with COVID-19, it stopped the development of more severe symptoms, accelerated their recovery, and allowed them to leave hospital earlier.

The Conversation by The Conversation
25-07-2020 01:45
in News
Multiple sclerosis drug may help treat COVID-19

Multiple sclerosis drug may help treat COVID-19 Photo by Mika Baumeister on Unsplash

Nial Wheate, University of Sydney and Elise Schubert, University of Sydney

What do multiple sclerosis (MS) and the novel coronavirus have in common? Until this week, not much, but a recent clinical trial has shown a reformulation of a drug used to treat MS can potentially also be used to help patients infected with COVID-19.

Vadim Zakharishchev/Shutterstock

SNG001 is an inhaled form of a drug called interferon-beta under development by the UK pharmaceutical company Synairgen. Interferon is normally prescribed for the treatment of symptoms relating to relapsing-remitting MS.

But the clinical trial, Synairgen found that when SNG001 was given to patients with COVID-19, it stopped the development of more severe symptoms, accelerated their recovery, and allowed them to leave hospital earlier.

Like other clinical trials for COVID-19 treatments, the results still need to be thoroughly checked before SNG001 is included as a standard treatment for coronavirus. The drug’s key risks (potential for severe depression) also need to be weighed against the potential benefits.

How does it work?

MS is a condition of the central nervous system. The nerve impulses between the brain and spinal cord get blocked or mixed up. It happens because the body’s immune system attacks the protective layers around nerve fibres. The result is a loss of muscle control and balance.

In contrast, COVID-19 is a viral infection that affects a patient’s ability to breathe due to inflammation putting pressure on their lungs.

AlsoRead...

Environmental impact

Pollinators: neonicotinoid pesticides stop bees and flies from getting a good night’s sleep

24 January 2021
Players risk losing fitness

Self-entitled prima donnas or do they have a point? Why Australian Open tennis players find hard lockdown so tough

24 January 2021

What both diseases have in common is the activation of the body’s immune response, so a drug that modulates the immune system for one can potentially work for the other.

Interferon-beta (interferon), a naturally occurring protein in the body, is used as an immunotherapy drug to combat relapsing-remitting MS by reducing inflammation and easing the symptoms of the disease.

Scientists at Synairgen hypothesised it could also treat COVID-19 through initiating the body’s antiviral response and potentially reducing inflammation on the lungs.

It is believed some at-risk patient groups cannot produce interferon as effectively as other people, reducing their ability to fight the virus and resulting in more severe symptoms.

So giving those patients interferon, in theory, should help them fight the virus, alleviate their symptoms, and improve survival rates.

Take a breath

For the treatment of MS, interferon is given as a weekly injection into muscle tissue.

The SNG001 drug developed by Synairgen contains the same interferon therapy used for MS, but formulated as an inhaled product.

Originally, the company was developing SNG001 as a treatment for a different type of lung condition called chronic obstructive pulomary diease (COPD), but it saw the direct potential for COVID-19 as well.

Instead of an injection, SNG001 is given to patients via a nebuliser, a machine that transforms a water solution of interferon into a fine mist that can be breathed in by patients through a face mask.

Promising results, so far

Between March and May this year, Synairgen sponsored a clinical trial at University Hospital Southampton to test SNG001 for COVID-19 patients. Those eligible for the trial only needed to have mild symptoms of COVID-19.

Other clinical trials conducted in the past for different drugs, such as remdesivir and dexamethasone, required patients to be hospitalised before they were eligible for drug treatment.

In total, 101 patients in a hospital setting were enrolled in the SNG001 trial and were given the drug daily for 14 days. Compared with a placebo, those given SNG001 had a 79% lower risk of developing severe disease.

Patients given the drug were also twice as likely to recover from their infection and were discharged earlier from hospital than those given the placebo.

Before SNG001 becomes standard care for COVID-19 treatment the results of the clinical trial need to be checked by independent scientists.

In the past, trial results for hydroxychloroquine did not stand up to scrutiny after they were announced and the results were subsequently retracted by the research team.

The risks and benefits

If the latest results are shown to be reliable, before doctors decide to make SNG001 a part of the standard treatment for hospitalised COVID-19 patients they will need to weigh its benefits against the potential risks.

One of the most important side effects of the drugs is that it can induce depression.

As a result, interferon is used with caution in patients with pre-existing depression or who have suicidal thoughts. These conditions may already be heightened by the pandemic if a potential patient for the drug has lost their job or they are not dealing well with the isolation of social distancing.

This means doctors would need to undertake a comprehensive mental health screen of all patients they consider for SNG001 treatment.

Other side effects relevant to interferon are that it can worsen seizure disorders or heart failures. So again, it needs to be used with caution in these patient groups.

The results of the SNG001 trial are very promising and potentially give us a treatment to prevent those people mildly infected with COVID-19 from developing more severe symptoms and needing hospitalisation.

But the results need to be checked by independent scientists first, and the drug’s benefits need to be weighed against its risk, as the ability to induce severe depression could cause a wave of mental health problems that make matters worse rather than better.

Nial Wheate, Associate Professor | Program Director, Undergraduate Pharmacy, University of Sydney and Elise Schubert, Pharmacist and PhD Candidate, University of Sydney

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Tags: SB001
DMCA.com Protection Status

SUBSCRIBE to our NEWSLETTER

Terms and Conditions

CURRENCY ZONE

Australian Forex

Don't Miss

Pollinators: neonicotinoid pesticides stop bees and flies from getting a good night’s sleep

by The Conversation
24 January 2021
Environmental impact
News

Neonicotinoids, the most commonly used pesticides in the world, were banned in the EU in 2018. More than 99,000 people...

Read more

Self-entitled prima donnas or do they have a point? Why Australian Open tennis players find hard lockdown so tough

by The Conversation
24 January 2021
Players risk losing fitness
News

The challenge of bringing the world’s best tennis players and support staff, about 1,200 people in all, from COVID-ravaged parts...

Read more

Why the COVID-19 variants are so dangerous and how to stop them spreading

by The Conversation
24 January 2021
COVID-19 variants
News

Changes in the genetic code of viruses like COVID-19 occur all the time but most of these mutations don’t have...

Read more

Gulf blockade: Qatar hugs and makes up with its warring neighbours – but will it last?

by The Conversation
24 January 2021
Gulf blockade
News

Qatar may be the smallest of the Gulf states – but it’s the richest. So when, hours after the agreement,...

Read more

Davos 2021: to achieve a ‘great reset’, we can’t count on the same old globalists to lead the way

by The Conversation
23 January 2021
The great reset
News

The 51st World Economic Forum starts on January 25, but with a major difference. Whereas this is famously the annual...

Read more

Gene-edited crops are now a reality – but will the public be on board?

by The Conversation
23 January 2021
Gene-edited crops
News

Whereas GM crops typically contain the DNA of two different species, gene editing is more precise and allows scientists to...

Read more

Lotto Results for Saturday, 23 January 2021

by Sonja Baartman
23 January 2021
Lottery Results Lotto Numbers UK
UK Lotto

Are you ready for the National Lottery Lotto draw? Let's find out if you're an overnight millionaire

Read more
Load More

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status

  • About us
  • Write for Us
  • Advertise
  • Contact us
  • T&Cs, Privacy and GDPR
No Result
View All Result
  • News
  • Lifestyle
    • Recipes
    • Video
    • Lotto Results
    • Technology
  • Entertainment
  • Travel
  • Sport
  • Expat Life
  • Move to Australia

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status